Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012

Blood Research
Eun-Hye ParkHyeon Jin Park

Abstract

Large-scale epidemiologic analysis for hematologic malignancies will be helpful to understand the trends in incidence and survival. The Korea Central Cancer Registry (KCCR) updated the nationwide analysis on the incidence and survival of myeloid malignancies, from the Korean National Cancer Incidence Database between 1999 and 2012. Myeloid malignancies were classified based on the International Classification of Diseases for Oncology 3(rd) edition (ICD-O-3). Overall 3,771 cases of myeloid diseases, which was 1.7% of all cancers, were identified in 2012. The highest incidence of myeloid malignancies was observed in age 70s and male predominance was noted (1.3:1). Acute myeloid leukemia (AML) was the most frequent subtype, followed by myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) and MDS/MPN: age-standardized incidence rates (ASR) in 2012 for each disease were 2.02, 1.95, 1.13, and 0.12 per 100,000 persons, respectively. The ASR for all myeloid malignancies was increased from 3.31 in 1999 to 5.70 in 2012 with the annual percentage change (APC) of 5.4 %. Five-year relative survival rate (RS) for myeloid malignancies has gradually improved for decades. RS changed from 26.3% to 34.8% in AML, specifically from 51...Continue Reading

References

Jun 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F E Alexander
Dec 26, 2003·Statistics in Medicine·Paul W DickmanTimo Hakulinen
Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Aug 22, 2006·Leukemia Research·Giuseppe GoriniAdele Seniori Costantini
Apr 2, 2009·Haematologica·Richard A Larson
Dec 1, 2005·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hai-Rim ShinUNKNOWN Members of the Regional Cancer Registries
Mar 13, 2010·Cancer Treatment Reviews·Tim Eden
Nov 26, 2010·The New England Journal of Medicine·Ted A GooleyGeorge B McDonald
Feb 19, 2011·Haematologica·Rafael Marcos-GrageraUNKNOWN HAEMACARE Working Group
Sep 18, 2012·Haematologica·Marc MaynadiéUNKNOWN HAEMACARE Working Group
Oct 25, 2012·Aesthetic Plastic Surgery·Percy Rossell-Perry, Percy Paredes-Leandro
May 23, 2014·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Kyu-Won JungJin Soo Lee

❮ Previous
Next ❯

Citations

Nov 15, 2017·The Korean Journal of Internal Medicine·Yunsuk ChoiJe-Hwan Lee
Aug 24, 2016·Journal of Korean Medical Science·Yoojoo LimSoo Mee Bang
Jul 19, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Yoo-Rin Cho, Yang-Sook Yoo
Sep 9, 2016·The Korean Journal of Internal Medicine·Junshik Hong, Jae Hoon Lee
Jul 14, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Silvia ParkHee-Je Kim
Jul 18, 2021·Current Oncology Reports·Sonia Jaramillo, Richard F Schlenk

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS

Software Mentioned

SAS
HAEMACARE
EUROCARE

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.